US20050070942A1 - Device for lifting an epitheleal layer and placing a corrective lens beneath it - Google Patents
Device for lifting an epitheleal layer and placing a corrective lens beneath it Download PDFInfo
- Publication number
- US20050070942A1 US20050070942A1 US10/956,511 US95651104A US2005070942A1 US 20050070942 A1 US20050070942 A1 US 20050070942A1 US 95651104 A US95651104 A US 95651104A US 2005070942 A1 US2005070942 A1 US 2005070942A1
- Authority
- US
- United States
- Prior art keywords
- lens
- epithelial
- tissue
- cornea
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/142—Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/145—Corneal inlays, onlays, or lenses for refractive correction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
Definitions
- This disclosure is in the field of ophthalmology. More particularly, it relates to a device for lifting an epithelial layer from the anterior surface of the cornea.
- the disclosure includes methods for placement of a lens beneath that epithelial layer.
- the visual system allows the eye to focus light rays into meaningful images.
- the most common problem an ophthalmologist or optometrist will encounter is that of spherical ammetropia, or the formation of an image by the eye which is out of focus with accommodation due to an improperly shaped globe.
- the ophthalmologist or optometrist determines the refractive status of the eye and corrects the optical error with contact lenses or glasses.
- the procedures in early corneal refractive surgery such as keratophakia and keratomileusis were originally developed to correct myopia and involved removing a corneal disc from the patient with a microkeratome. The removed corneal disc was then frozen prior to reshaping the posterior surface with a cryolathe. After thawing, the disc was returned to the eye and secured with sutures.
- Epikeratophakia as described in U.S. Pat. No. 4,662,881, is a procedure that involves inserting a precut donor corneal tissue lens with beveled edges into corresponding grooves in recipient cornea. The lens is then sutured to the corneal bed. The donor lens is lyophilized and requires rehydration before placement on recipient cornea.
- a pre-fabricated lens made of donor corneal tissue obtained from tissue sources such as human or animal cornea.
- the lens is a corneal disc that is preferably shaped on the posterior surface generally to conform in shape to the eye's anterior surface.
- the lens may be shaped by an ablative laser, e.g., by an excimer laser or other suitable laser.
- the corneal lenticule is living tissue that has not been frozen, lyophilized, or chemically modified, e.g., fixed with glutaraldehyde to crosslink corneal tissue.
- Pre-existing keratocytes are removed and then replaced with human keratocytes to decrease antigenicity. After removal of epithelium in the central zone of the recipient's cornea, the lens is placed on this zone in the same manner that a contact lens is placed on the eye.
- Ocular lenses found in the prior art do not use native cornea, but are formulated using soluble collagen such as collagen hydrogels, e.g., polyhydroxyethylmethacrylate, or other biocompatible materials.
- soluble collagen such as collagen hydrogels, e.g., polyhydroxyethylmethacrylate, or other biocompatible materials.
- soluble collagen is gelled and crosslinked to produce an artificial lens.
- U.S. Pat. No. 4,715,858, to Lindstrom discloses lenses made from various polymers, silicone, and cellulose acetate butyrate.
- ocular lenses In the cases where ocular lenses use corneal tissue, the lenses are either corneal implants or require a separate agent to adhere the lens to the corneal bed.
- U.S. Pat. No. 5,171,318, to Gibson et al., and U.S. Pat. No. 5,919,185, to Peyman relate to a disc of corneal tissue that is partially or entirely embedded in stroma.
- the ocular lens device disclosed in U.S. Pat. No. 4,646,720, to Peyman et al., and U.S. Pat. No. 5,192,316, to Ting is attached to recipient cornea with sutures.
- the corneal inlay described in U.S. Pat. No. 4,676,790, to Kern is bonded to recipient cornea using sutures, laser welding, or application of a liquid adhesive or crosslinking solution.
- U.S. Pat. No. 4,346,482 to Tennant et al. discloses a “living contact lens” consisting of donor cornea that has been anteriorly curved for correction of vision. However, this lens is frozen prior to reshaping on a lathe which results in stromal keratocyte death.
- U.S. Pat. No. 4,793,344, to Cumming et al. also describes a donor corneal tissue lens that is modified by treatment with a glutaraldehyde fixative that preserves the tissue and prevents lens swelling. This treatment alters the basic structure of the corneal lenticule by crosslinking the tissue.
- the cited documents do not show any methods of lens preparation that remove native corneal tissue cells and replace them with cells cultivated from human cornea.
- My device is devitalized of native epithelium and keratocytes to create an acellular corneal tissue, and then revitalized with human epithelium and keratocytes.
- An attempt to construct a so-called “corneal tissue equivalent” was shown in U.S. Pat. No. 5,374,515, to Parenteau et al.
- the collagen used in that “equivalent” is obtained from bovine tendon instead of from cornea.
- the added keratocytes and epithelium are also not from human sources.
- the tissue using these cell culturing procedures is also quite fragile.
- An excimer laser is used to reform a cornea via the “laser in situ keratomileusis” (LASIK) procedure.
- LASIK laser in situ keratomileusis
- an excimer laser is used to perform stromal photoablation of a corneal flap or in situ photoablation of the exposed stromal bed.
- the inaccuracy of correction by this procedure may be as much as one diopter from the desired value.
- Lenses contacts and spectacles
- My described lens in some variations relates to a pre-fabricated donor contact lens that adheres to recipient cornea without sutures.
- the lens preserves the anatomy of normal corneal tissue.
- the donor lens may be obtained from human and animal sources, is devitalized of native keratocytes and epithelium to create an acellular tissue, and then optionally revitalized with at least one of human keratocytes and epithelial cells to maintain lens viability and decrease antigenicity.
- the inventive corneal overlay technique may be completed under local anesthesia as well as general anesthesia, and the availability of a precut lens will greatly decrease procedure time, patient cost, and risk of operative complications. The duration of healing will also be reduced due to the implementation of a lens already repopulated with keratocytes.
- a pre-fabricated ocular lens device having a lens core made of donor corneal tissue from tissue sources such as human or animal cornea.
- the device may be used as a contact lens or as an implanted lens and may have a generally convex anterior surface and, optionally, a concave posterior surface.
- the stroma portion of the lens core may be repopulated with replaced keratocytes and the anterior surface is preferably covered with a replaced epithelium.
- the lens core adheres to recipient cornea without sutures or other adhering materials.
- the lens core may be variously used to correct astigmatism, myopia, aphakia, and presbyopia.
- the lens core may be made of transgenic or xenogenic corneal tissue.
- the inventive lens may have a clarity at least 85% of that of human corneal tissue of a corresponding thickness.
- the lens core is not frozen, lyophilized, or chemically treated with a fixative.
- variations of the device may contain therapeutic agents, growth factors, or immunosuppressive agents.
- Another component is a method for preparing the lens device. After sharp dissection of a lenticule from donor corneal tissue, the posterior surface is shaped using an ablative laser, such as an excimer laser or other suitable shaping lasers. Native epithelium and keratocytes are removed and then replaced, as desired, with human epithelium and keratocytes.
- an ablative laser such as an excimer laser or other suitable shaping lasers.
- a method of corneal overlay that involves de-epithelialization of a portion of the anterior surface of the recipient cornea and placement of the inventive ocular lens device upon that anterior surface.
- Another method involves the temporary separation of the epithelial tissue by suction or other procedures and placement of a lens beneath that epithelial tissue.
- FIG. 1 is a superior, cross-sectional view of the eye.
- FIG. 2A is a side view of the focusing point in myopia.
- FIG. 2B is a side view of a focusing point corrected by flattening the anterior curvature of the cornea.
- FIG. 3A is a side, cross-sectional view of a pre-fabricated donor lens.
- FIG. 3B is a side, cross-sectional view of a pre-fabricated donor lens suitable for correcting myopia.
- FIG. 3C is a side, cross-sectional view of a pre-fabricated donor lens suitable for correcting aphakia.
- FIG. 3D is a front view of a pre-fabricated donor lens suitable for bifocal use.
- FIG. 3E is a side, cross-sectional view of the FIG. 3C lens positioned away from the cornea of an eye.
- FIG. 3F is a front view of an inventive lens having an overlapping epithelial layer.
- FIG. 3G shows a side cross sectional view of the FIG. 3F lens.
- FIG. 3H shows a side cross sectional view of an inventive lens in a carrier.
- FIG. 3I is a front view of an annular inventive lens.
- FIG. 3J shows a side cross sectional view of the FIG. 31 lens.
- FIG. 4A is a side, cross-sectional view of an area of de-epithelialized recipient cornea prepared to receive the optical lens of the present invention.
- FIG. 4B is a side, cross-sectional view of the donor lens after placement on recipient cornea.
- FIG. 5 show a series of steps for introducing an inventive lens subepithelially.
- the eye is designed to focus light onto specialized receptors in the retina that turn quanta of light energy into nerve action potentials.
- light rays are first transmitted through the cornea ( 100 ) of the eye.
- the cornea is transparent due to the highly organized structure of its collagen fibrils.
- the margins of the cornea merge with a tough fibrocollagenous sclera ( 102 ) and is referred to as the corneo-scleral layer.
- the cornea ( 100 ) is the portion of the corneo-scleral layer enclosing the anterior one-sixth of the eye.
- the smooth curvature of the cornea is the major focusing power of images on the retina ( 104 ) and it provides much of the eye's 60 diopters of converging power.
- the cornea is an avascular structure and is sustained by diffusion of nutrients and oxygen from the aqueous humor ( 106 ). Some oxygen is also derived from the external environment.
- the avascular nature of the cornea decreases the immunogenicity of the tissue, increasing the success rate of corneal transplants.
- the cornea consists of five layers.
- the outer surface is lined by stratified squamous epithelium which is about five cells thick. Failure of epithelialization results in necrosis of the stromal cap and potential scarring of recipient cornea.
- the epithelium is supported by a specialized basement membrane known as Bowman's membrane, which gives the cornea a smooth optical surface.
- the bulk of the cornea, the substantia basement (stroma) consists of a highly regular form of dense collagenous connective tissue forming thin lamellae. Between the lamellae are spindle-shaped keratocytes which can be stimulated to synthesize components of the connective tissue.
- the inner surface of the cornea is lined by a layer of flattened endothelial cells which are supported by Descemet's membrane, a very thick elastic basement membrane.
- the focusing power of the cornea is primarily dependent on the radius of curvature of its external surface.
- myopia as seen in FIG. 2A , increased curvature of the cornea ( 200 ) causes the focusing point of light rays ( 202 ) to fall short of the retina ( 204 ).
- FIG. 2B flattening the anterior curvature of the cornea ( 206 ) corrects the focal point ( 208 ).
- the physical shape generally is of a size and configuration that upon installation on the cornea, supplements the curvature of the cornea to correct abnormal conditions such as astigmatism, myopia, hyperopia, presbyopia, and aphakia.
- Other variations of the lens may be shaped to be placed beneath the anterior surface of the host cornea or to serve as a source of medication.
- the lens core may comprise or consist essentially of acellular donor corneal tissue that has been devitalized, e.g., treated to remove native keratocytes and epithelium, to lessen the chances of tissue rejection and then at least partially revitalized, e.g., treated to introduce at least one of human keratocytes and an epithelial layer, to allow and to support continued use of the inventive lens in place on the eye.
- the epithelial cells may (often in the form of a discrete layer) be placed on at least a portion of the anterior surface of a lens. In some variations, all of the anterior surface will be so-covered. In one variation discussed below, an epithelial layer will extend beyond the periphery of the lens core and optionally the lens be carried in a biodegradable carrier that is used during placement in the eye and later disappears.
- the described lens may be placed on a host eye from which at least a major portion of the native epithelium on that cornea, has been removed. Preferably in this variation, substantially all of the epithelium has been removed from the region upon which the inventive lens will be sited.
- the lens may also be placed beneath a layer of epithelium lifted from the eye surface during the procedure of introducing the lens onto the anterior surface of the host cornea or in other instances beneath the surface of the host cornea.
- the described lens may be used variously to correct refraction (because of its shape) or it may be used simply to provide a source of infused medication to the eye.
- the donor lenticule or lens core may be obtained from other human (allogeneic) or foreign tissue (xenogenic) sources.
- Appropriate xenogenic sources include rabbit, bovine, porcine, or guinea pig corneal tissue.
- the ocular lens cores may also come from transgenic corneal tissue or corneal tissue grown in vitro. In many instances, it is desired that the architecture of the corneal layers in the donated tissue, the normal corneal tissue matrix, e.g., the connective tissue or the stroma, be substantially preserved.
- the “corneal tissue matrix” is made up of thin layers of collagen fibrils.
- the term “donor corneal tissue”, as used here, is meant to include donor or harvested corneas or corneal tissue containing the “corneal tissue matrix”.
- the donor corneal tissue is not to undergo harsh treatments such as lyophilization, freezing, or other chemical fixation. Nevertheless, it is sometimes desirable to utilize only a portion of the anterior surface of the donor lens, e.g., in those instances where the inventive lens structure is annular in shape.
- the described ocular lens device desirably includes Bowman's membrane, where the donor tissue includes it, to maintain the native structure of human epithelium.
- Bowman's membrane where the donor tissue includes it, to maintain the native structure of human epithelium.
- the clarity of the inventive tissue lens core handled in such a way generally will be at least 85%, preferably between 75%-100%, and most preferably at least 90%, of that of human corneal tissue of corresponding thickness.
- the overall diameter of my lens is functionally appropriate to perform the desired correction, and generally is less than about 25 mm and more preferably is between 10 and 15 mm.
- the thickness of the resulting lens is, again, functionally appropriate to perform the desired correction, e.g., generally less than 300 ⁇ m, more preferably between 5-100 ⁇ m.
- a lens core ( 316 ) for myopic patients is formed, preferably using the procedures discussed below, in such a way that a generally circular region ( 318 ) in the center is flattened in its anterior curvature.
- a lens such as is shown in FIG. 3C is formed having a comparatively thicker center ( 322 ) and a thinner perimeter ( 324 ).
- the shapes discussed here are similar to those found in the so-called “soft” contact lenses and instruction may be had from that technology relating to the overall form of the lenses selected for correcting specific ocular maladies.
- the lens may also be used to correct presbyopia.
- the lens ( 330 ) is also provided with an generally opaque annular region ( 332 ) adjacent the center of the device.
- the open center ( 334 ) preferably has plano-lens characteristics and an effective diameter of less than about 1.5 mm, preferably between about 0.5-1.5 mm, and most preferably between 0.75 mm and 1.75 mm.
- the diameter of that open center ( 334 ) or central area or “pinhole” is generally formed and selected to be less than the pupillary diameter of the host eye in daylight.
- bifocal lens designs can also be incorporated, e.g., concentric rings, segmented or sectors of the annular region or ring, or progressive diffractive.
- FIG. 3E shows a side, cross-sectional view of my lens ( 330 ) shown in FIG. 3D , adjacent the anterior surface of a cornea ( 344 ) to illustrate certain features of this variation.
- the outer diameter ( 336 ) of the opaque annular ring ( 332 ) is generally selected so that it is smaller than the diameter ( 338 ) of the pupil ( 340 ) in the iris ( 342 ) in low light conditions.
- the eye's cornea and lens and the inventive lens cooperate in such a way that incident light passes both though the center of the opaque ring ( 334 ), but more importantly, around the periphery of the opaque ring ( 332 ), to allow corrected sight during low light conditions.
- the annular ring ( 332 ) may be situated on the lens core either by placement of a suitable dye, i.e., by “tattooing”, or by placement of a substantially opaque biocompatible member of, e.g., Dacron mesh or the like, on the posterior surface to filter light rays. Other placements of the annular ring ( 332 ) may be envisioned, e.g., on the anterior surface of the inventive lens.
- the annular ring ( 332 ) itself preferably is quite opaque, e.g., passing less than about 80% of incident visible light, but may be chosen in such a way to be less opaque or to correct other maladies such as colorblindness by shifting an incident color into a visible range by color refraction or the like.
- another variation of the lens device ( 346 ) includes a core lens ( 348 ) as discussed above but having an epithelial layer ( 352 ) that extends beyond the periphery ( 350 ) of that lens core ( 348 ).
- the method for producing the variation ( 346 ) with an extra-periphery epithelial layer ( 352 ) is similar to the method described elsewhere herein except that the lens core ( 348 ) is desirably placed in a carrier ( 354 in FIG. 3H )) having a shape generally conforming to the anterior surface of the donor core lens ( 348 ).
- the carrier ( 354 ), as shown in FIG. 3H , desirably serves several functions. First, it provides a substrate for growth of the epithelial layer ( 352 ) prior to the time that the core lens ( 348 ) is placed on that epithelial layer ( 352 ). This extra surface beyond the periphery of the core lens ( 348 ) provides support for the otherwise fragile epithelial layer ( 352 ).
- the carrier ( 354 ) may be placed in or formed in a properly shaped receptacle that, in turn, provides support for the fragile carrier ( 354 ) during the steps of growing an epithelial layer ( 352 ).
- the construct ( 356 ) shown in FIG. 3H may, upon proper choice of materials for the carrier, be placed directly in the host eye thereby providing support for the epithelial layer ( 352 ) and core lens ( 348 ), as well as optionally, medication or other treatment materials for the eye during initial placement.
- the carrier ( 354 ) preferably comprises a material meeting two related criteria.
- the material desirably is one that dissolves, erodes, or otherwise shortly clears from the eye to be treated after the combination ( 356 ) of the carrier ( 354 ), epithelial layer ( 352 ), and the donor lens ( 348 ) are introduced to that eye.
- the carrier is of a material that serves as a substrate for a pre-grown epithelial layer. Most desirably, the carrier ( 354 ) satisfies both criteria.
- the carrier ( 354 ) may comprise a material such as collagen, gelatin, starch, glucosamine glucans, proteins, carbohydrates, polyanhydrides such as polylactides and polyglycolides, their mixtures and copolymers, polydiaxanone, etc.
- the carrier ( 354 ) may also be infused with medication or other treatment material, antiangiogenesis materials or the like.
- FIGS. 3I and 3J show, respectively, a front view and a side cross sectional view of a lens ( 360 ) having a central opening ( 362 ) passing through the lens body.
- this lens variation ( 360 ) is shown without an epithelial layer, it is within the scope of the invention to so include the layer.
- the donor core lens ( 300 ) desirably is obtained after slicing corneal tissue from the donor with a microkeratome to form that lens core ( 300 ).
- the donor lens ( 300 ) has a structural surface, the anterior surface of the lens core, which serves as the structural surface of the donor corneal tissue.
- the lens core anterior surface is harvested preferably to retain the Bowman's membrane (where the donor lens contains one) and epithelium ( 302 ).
- the posterior surface ( 304 ) of the resulting lens is generally concave in shape, although it need not be so.
- the anterior surface of the lens may be shaped via a shaping step which preferably involves the use of an ablative laser, such as an excimer laser, to obtain the necessary power of the lens.
- Another suitable forming step is high pressure water jet cutting.
- the lens will first be shaped to an appropriate shape as discussed above.
- the lens core may then be subjected to processes of sterilization, devitalization, and revitalization.
- Removal of epithelium (de-epithelialization) and keratocytes (acellularization) from the donor lens will be referred to as “devitalization”.
- the addition of human epithelium and keratocytes will be referred to as “revitalization”.
- One desirable method for accomplishing those steps is found just below. Other equivalent methods are known.
- PBS with antibiotics Phosphate buffered saline (PBS) with antibiotics, epithelial cell media, and keratocyte media are solutions used during these processes.
- the “PBS with antibiotics” solution may contain:
- composition of the epithelial cell media may include:
- composition of the keratocyte media may include:
- the lens After harvesting the lens core from donor corneal tissue and following the shaping step, the lens may be sterilized, for instance, by immersion into 98% glycerol at room temperature. Three weeks of glycerol treatment inactivates intracellular viruses and any bacteria or fungi. Ethylene oxide gas sterilization may also be used, but tends to induce variable damage to stromal tissue.
- salt preferably sodium chloride
- the epithelium may be split from the stroma by means of suction ( ⁇ 100 mm Hg to ⁇ 450 mm Hg). After fifteen minute to 1 hour, the epithelium typically will separate from the stroma at the basement membrane layer. Thereafter the lens may be washed in a PBS solution with antibiotics to remove salt and cellular material.
- the donor lens may be de-epithelialized by placing it in sterile PBS with antibiotics for four hours and changing the solution many times.
- the lens core may then be kept submerged in the PBS solution at 37° C. for one week to produce a split between the epithelium and the stroma.
- the epithelium may then be removed, e.g., by physically scraping or washing with a liquid stream. Small numbers of lenses may be stripped of epithelium by gentle scraping with forceps.
- the de-epithelialized lens may be then immersed in a solution of detergent (for example 0.025% to 15% sodium dodecyl sulfate) to wash out the keratocyte cellular material.
- a detergent will solubilize and wash out the keratinocytic material. This can take place from 1 to 8 hours. Afterward the cellular material can be washed in a buffered solution with antibiotics to remove detergent and cellular material.
- the de-epithelialized lens may be immersed in sterile PBS with antibiotics for an appropriate period, e.g., several weeks, perhaps six weeks to remove native keratocytes.
- the solution may be changed twice weekly. In some instances, it may not be necessary to remove keratocytes from the donor lens, e.g., when the donor tissue is obtained from a transgenic source and has minimal antigenicity.
- Epithelial cells and keratocytes are used in the revitalization process.
- Epithelial cells may be obtained from a tissue bank, but are preferably obtained from fetal or neonatal tissue. Fetal cells are most preferable, since the properties of fetal tissue minimize scarring during any wound healing process.
- freshly isolated epithelial cells obtained by trypsinization of corneal tissue, may be seeded onto a precoated feeder layer of lethally irradiated 3T3 fibroblasts (i.3T3) in epithelial cell media.
- i.3T3 lethally irradiated 3T3 fibroblasts
- Cells are cultured and media changed every three days until the cells are 80% confluent, about 7-9 days. Residual i.3T3 are removed with 0.02% EDTA (Sigma-Aldrich) before the epithelial cells are detached using trypsin (ICN Biomedicals).
- Another method of regenerating epithelium involves culturing autologous epithelial cells on human amniotic membrane as described in Tsai et al. (2000). “Reconstruction of Damaged Corneas by Transplantation of Autologous Limbal Epithelial Cells,” New England Journal of Medicine 343:86-93.
- Keratocytes may be extracted from the remaining stromal tissue.
- the stroma is washed in PBS, finely minced, and placed in 0.5% collagenase A (ICN Biomedicals) at 37° C. for 16 hours. Keratocytes obtained from this enzyme digest are then serially cultured in keratocyte media.
- the epithelial cells and keratocytes generated in the revitalization step will be referred to as “replaced” epithelial cells and keratocytes.
- the acellular donor lens core may then be placed on a hydrophilic, polyelectrolyte gel for completion of the re-vitalization.
- the preferred polyelectrolytes are chondroitin sulfate, hyaluronic acid, and polyacrylamide. Most preferred is polyacrylic acid.
- the lens is immersed in keratocyte media and incubated with approximately 3 ⁇ 10 5 keratocytes for 48 hours at 37° C. Approximately the same amount of epithelial cells are then added to the anterior stromal surface. Tissue culture incubation continues for another 48 hours. Keratocyte media is changed every two to three days. Once the epithelium is regenerated, the polyelectrolyte gel draws water out of the lens at a pressure of about 20-30 mm Hg until the original lens dimensions are obtained.
- Replaced epithelium covers at least a portion of the anterior surface of this variation of the inventive lens and replaced keratocytes repopulate the stroma of the lens core after revitalization.
- another variation of the lens includes an epithelial layer ( 352 in FIG. 3G ) that extends from the periphery of the lens core ( 348 ).
- the same procedure as just outlined may be used to prepare the epithelial cell layer in the carrier ( 354 ) prior to placement of the lens core ( 348 ) onto the pre-prepared epithelial cell layer.
- FIGS. 4A and 4B One procedure for applying the lens of this invention is depicted in FIGS. 4A and 4B .
- the donor lens ( 300 ) As shown in FIG. 3A , is placed on a portion of recipient cornea that has been de-epithelialized ( 308 ). The result is the placement and construct ( 312 ) shown in FIG. 4B .
- the lens' replaced epithelium and the host epithelium eventually grow to form a continuous, water-tight layer ( 310 ). I have found that the inventive lens bonds or adheres to the recipient cornea without sutures or adhesives, but can also be removed without substantial difficulty.
- FIG. 5 Another placement procedure variation is shown in FIG. 5 .
- a core lens that has been only partially revitalized in that the keratocytes have been replaced but the epithelial layer has not.
- a core lens that has been partially covered with a seed layer of epithelial cells is also acceptable.
- step a. of FIG. 5 shows a native eye ( 600 ) having an epithelial layer ( 602 ) and a corneal stroma ( 604 ).
- Step b. of FIG. 5 shows the placement of a suction device ( 606 ) on the anterior surface of the eye ( 600 ).
- the suction device ( 606 ) applies a modest vacuum to the epithelial layer ( 602 ), e.g., between about ⁇ 100 mmHg and ⁇ 450 mmHg, to raise a section of the epithelial layer ( 602 ) as shown in step c.
- This blister ( 608 ) typically is filled with a physiologic fluid.
- the suction device ( 606 ) has a footprint on the surface of the cornea similar to the size of the lens to be placed on that cornea.
- Step d. shows the opened epithelial flap ( 608 ) and the placement of the lens towards the corneal stromal margin ( 612 ) beneath that epithelial flap ( 608 ).
- Step c. of FIG. 5 shows the finished placement of the lens ( 610 ) on the cornea beneath the native epithelial membrane. This procedure has a number of benefits including that of being less traumatic to the surface of the eye than simple removal of the epithelium.
- the preparation procedure for the LASEK procedure for the step of exposing the corneal surface for application of the lens.
- the LASEK procedure is known and, unlike the LASIK procedure, does not involve temporary removal of an anterior flap of corneal tissue with a surgical tool but rather only utilizes an ethanol wash and a temporary withdrawal of the epithelial layer for a laser treatment.
- the washing with ethanol to perturb the junction between the corneal stroma and the epithelium is adequate to provide a layer of epithelium for temporary movement and insertion of the inventive lens on the corneal surface.
Abstract
This relates to a lens made of donor corneal tissue suitable for use as a contact lens or an implanted lens, to a method of preparing that lens, and to a technique of placing the lens on the eye. The lens is made of donor corneal tissue that is acellularized by removing native epithelium and keratocytes. These cells optionally are replaced with human epithelium and keratocytes to form a lens that has a structural anatomy similar to human cornea. The ocular lens may be used to correct conditions such as astigmatism, myopia, aphakia, and presbyopia.
Description
- This is a continuation of pending U.S. patent application Ser. No. 10/243,121, filed Sep. 13, 2002, a continuation of PCT Application No. PCT/US01/22633, having an International Filing Date of Jul. 18, 2001, and a continuation-in-part of pending U.S. patent application Ser. No. 09/618,580, filed Jul. 18, 2000.
- This disclosure is in the field of ophthalmology. More particularly, it relates to a device for lifting an epithelial layer from the anterior surface of the cornea. The disclosure includes methods for placement of a lens beneath that epithelial layer.
- The visual system allows the eye to focus light rays into meaningful images. The most common problem an ophthalmologist or optometrist will encounter is that of spherical ammetropia, or the formation of an image by the eye which is out of focus with accommodation due to an improperly shaped globe. The ophthalmologist or optometrist determines the refractive status of the eye and corrects the optical error with contact lenses or glasses.
- Many procedures have been developed to correct spherical ammetropia by modifying the shape of the cornea. Light entering the eye is first focused by the cornea, which possesses approximately 75% of the eye's overall refractory power. The majority of refractive operations involve either decreasing or increasing the anterior curvature of the cornea.
- The procedures in early corneal refractive surgery such as keratophakia and keratomileusis were originally developed to correct myopia and involved removing a corneal disc from the patient with a microkeratome. The removed corneal disc was then frozen prior to reshaping the posterior surface with a cryolathe. After thawing, the disc was returned to the eye and secured with sutures.
- Epikeratophakia, as described in U.S. Pat. No. 4,662,881, is a procedure that involves inserting a precut donor corneal tissue lens with beveled edges into corresponding grooves in recipient cornea. The lens is then sutured to the corneal bed. The donor lens is lyophilized and requires rehydration before placement on recipient cornea.
- These techniques and their variations were generally considered to be unsuccessful due to frequent complications involving irregular astigmatism, delayed surgical healing, corneal scarring, and instability of the refractive result. The problems were attributed to the technical complexity of the procedures as well as to the distortion in architecture of the corneal tissue secondary to lens manipulation. For example, in epikeratophakia, epithelial irregularity is induced by lyophilization of the donor lens. Freezing of the lenticule in keratophakia and keratomileusis also causes severe damage to epithelial and stromal cells and disrupts the lamellar architecture of the cornea.
- Described is a pre-fabricated lens made of donor corneal tissue obtained from tissue sources such as human or animal cornea. The lens is a corneal disc that is preferably shaped on the posterior surface generally to conform in shape to the eye's anterior surface. The lens may be shaped by an ablative laser, e.g., by an excimer laser or other suitable laser. The corneal lenticule is living tissue that has not been frozen, lyophilized, or chemically modified, e.g., fixed with glutaraldehyde to crosslink corneal tissue. Pre-existing keratocytes are removed and then replaced with human keratocytes to decrease antigenicity. After removal of epithelium in the central zone of the recipient's cornea, the lens is placed on this zone in the same manner that a contact lens is placed on the eye.
- Ocular lenses found in the prior art do not use native cornea, but are formulated using soluble collagen such as collagen hydrogels, e.g., polyhydroxyethylmethacrylate, or other biocompatible materials. For example, in U.S. Pat. No. 5,213,720, to Civerchia, soluble collagen is gelled and crosslinked to produce an artificial lens. In addition to hydrogels, U.S. Pat. No. 4,715,858, to Lindstrom, discloses lenses made from various polymers, silicone, and cellulose acetate butyrate.
- In the cases where ocular lenses use corneal tissue, the lenses are either corneal implants or require a separate agent to adhere the lens to the corneal bed. U.S. Pat. No. 5,171,318, to Gibson et al., and U.S. Pat. No. 5,919,185, to Peyman, relate to a disc of corneal tissue that is partially or entirely embedded in stroma. The ocular lens device disclosed in U.S. Pat. No. 4,646,720, to Peyman et al., and U.S. Pat. No. 5,192,316, to Ting, is attached to recipient cornea with sutures. The corneal inlay described in U.S. Pat. No. 4,676,790, to Kern, is bonded to recipient cornea using sutures, laser welding, or application of a liquid adhesive or crosslinking solution.
- The ocular lens device described here does not alter the anatomical structure of corneal tissue. U.S. Pat. No. 4,346,482, to Tennant et al., discloses a “living contact lens” consisting of donor cornea that has been anteriorly curved for correction of vision. However, this lens is frozen prior to reshaping on a lathe which results in stromal keratocyte death. U.S. Pat. No. 4,793,344, to Cumming et al., also describes a donor corneal tissue lens that is modified by treatment with a glutaraldehyde fixative that preserves the tissue and prevents lens swelling. This treatment alters the basic structure of the corneal lenticule by crosslinking the tissue.
- Furthermore, the cited documents do not show any methods of lens preparation that remove native corneal tissue cells and replace them with cells cultivated from human cornea. My device is devitalized of native epithelium and keratocytes to create an acellular corneal tissue, and then revitalized with human epithelium and keratocytes. An attempt to construct a so-called “corneal tissue equivalent” was shown in U.S. Pat. No. 5,374,515, to Parenteau et al. However, the collagen used in that “equivalent” is obtained from bovine tendon instead of from cornea. The added keratocytes and epithelium are also not from human sources. The tissue using these cell culturing procedures is also quite fragile.
- An excimer laser is used to reform a cornea via the “laser in situ keratomileusis” (LASIK) procedure. In this technique, an excimer laser is used to perform stromal photoablation of a corneal flap or in situ photoablation of the exposed stromal bed. Studies have shown that the inaccuracy of correction by this procedure may be as much as one diopter from the desired value. Lenses (contacts and spectacles), in contrast, are able to correct within 0.25 diopters of the desired value.
- U.S. Pat. No. 6,036,683, to Jean et al., shows the use of a laser to reshape the cornea. However, the laser changes the native structure of the cornea by irreversibly coagulating collagen. Post-laser relaxation of collagen is not possible with this treatment.
- My described lens, however, in some variations relates to a pre-fabricated donor contact lens that adheres to recipient cornea without sutures. The lens preserves the anatomy of normal corneal tissue. The donor lens may be obtained from human and animal sources, is devitalized of native keratocytes and epithelium to create an acellular tissue, and then optionally revitalized with at least one of human keratocytes and epithelial cells to maintain lens viability and decrease antigenicity. The inventive corneal overlay technique may be completed under local anesthesia as well as general anesthesia, and the availability of a precut lens will greatly decrease procedure time, patient cost, and risk of operative complications. The duration of healing will also be reduced due to the implementation of a lens already repopulated with keratocytes.
- None of the cited documents shows or suggest the lens and procedures described herein.
- Described is a pre-fabricated ocular lens device having a lens core made of donor corneal tissue from tissue sources such as human or animal cornea. The device may be used as a contact lens or as an implanted lens and may have a generally convex anterior surface and, optionally, a concave posterior surface. The stroma portion of the lens core may be repopulated with replaced keratocytes and the anterior surface is preferably covered with a replaced epithelium. The lens core adheres to recipient cornea without sutures or other adhering materials.
- The lens core may be variously used to correct astigmatism, myopia, aphakia, and presbyopia. The lens core may be made of transgenic or xenogenic corneal tissue. Properly treated, the inventive lens may have a clarity at least 85% of that of human corneal tissue of a corresponding thickness. The lens core is not frozen, lyophilized, or chemically treated with a fixative. However, variations of the device may contain therapeutic agents, growth factors, or immunosuppressive agents.
- Another component is a method for preparing the lens device. After sharp dissection of a lenticule from donor corneal tissue, the posterior surface is shaped using an ablative laser, such as an excimer laser or other suitable shaping lasers. Native epithelium and keratocytes are removed and then replaced, as desired, with human epithelium and keratocytes.
- Also described is a method of corneal overlay that involves de-epithelialization of a portion of the anterior surface of the recipient cornea and placement of the inventive ocular lens device upon that anterior surface. Another method involves the temporary separation of the epithelial tissue by suction or other procedures and placement of a lens beneath that epithelial tissue.
-
FIG. 1 is a superior, cross-sectional view of the eye. -
FIG. 2A is a side view of the focusing point in myopia. -
FIG. 2B is a side view of a focusing point corrected by flattening the anterior curvature of the cornea. -
FIG. 3A is a side, cross-sectional view of a pre-fabricated donor lens. -
FIG. 3B is a side, cross-sectional view of a pre-fabricated donor lens suitable for correcting myopia. -
FIG. 3C is a side, cross-sectional view of a pre-fabricated donor lens suitable for correcting aphakia. -
FIG. 3D is a front view of a pre-fabricated donor lens suitable for bifocal use. -
FIG. 3E is a side, cross-sectional view of theFIG. 3C lens positioned away from the cornea of an eye. -
FIG. 3F is a front view of an inventive lens having an overlapping epithelial layer. -
FIG. 3G shows a side cross sectional view of theFIG. 3F lens. -
FIG. 3H shows a side cross sectional view of an inventive lens in a carrier. -
FIG. 3I is a front view of an annular inventive lens. -
FIG. 3J shows a side cross sectional view of theFIG. 31 lens. -
FIG. 4A is a side, cross-sectional view of an area of de-epithelialized recipient cornea prepared to receive the optical lens of the present invention. -
FIG. 4B is a side, cross-sectional view of the donor lens after placement on recipient cornea. -
FIG. 5 show a series of steps for introducing an inventive lens subepithelially. - The eye is designed to focus light onto specialized receptors in the retina that turn quanta of light energy into nerve action potentials. As shown in
FIG. 1 , light rays are first transmitted through the cornea (100) of the eye. The cornea is transparent due to the highly organized structure of its collagen fibrils. The margins of the cornea merge with a tough fibrocollagenous sclera (102) and is referred to as the corneo-scleral layer. - The cornea (100) is the portion of the corneo-scleral layer enclosing the anterior one-sixth of the eye. The smooth curvature of the cornea is the major focusing power of images on the retina (104) and it provides much of the eye's 60 diopters of converging power. The cornea is an avascular structure and is sustained by diffusion of nutrients and oxygen from the aqueous humor (106). Some oxygen is also derived from the external environment. The avascular nature of the cornea decreases the immunogenicity of the tissue, increasing the success rate of corneal transplants.
- The cornea consists of five layers. The outer surface is lined by stratified squamous epithelium which is about five cells thick. Failure of epithelialization results in necrosis of the stromal cap and potential scarring of recipient cornea. The epithelium is supported by a specialized basement membrane known as Bowman's membrane, which gives the cornea a smooth optical surface. The bulk of the cornea, the substantia propria (stroma), consists of a highly regular form of dense collagenous connective tissue forming thin lamellae. Between the lamellae are spindle-shaped keratocytes which can be stimulated to synthesize components of the connective tissue. The inner surface of the cornea is lined by a layer of flattened endothelial cells which are supported by Descemet's membrane, a very thick elastic basement membrane.
- As previously mentioned, the focusing power of the cornea is primarily dependent on the radius of curvature of its external surface. In myopia, as seen in
FIG. 2A , increased curvature of the cornea (200) causes the focusing point of light rays (202) to fall short of the retina (204). InFIG. 2B , flattening the anterior curvature of the cornea (206) corrects the focal point (208). - In a first variation of the described lens, the physical shape generally is of a size and configuration that upon installation on the cornea, supplements the curvature of the cornea to correct abnormal conditions such as astigmatism, myopia, hyperopia, presbyopia, and aphakia. Other variations of the lens may be shaped to be placed beneath the anterior surface of the host cornea or to serve as a source of medication.
- Typically, the lens core may comprise or consist essentially of acellular donor corneal tissue that has been devitalized, e.g., treated to remove native keratocytes and epithelium, to lessen the chances of tissue rejection and then at least partially revitalized, e.g., treated to introduce at least one of human keratocytes and an epithelial layer, to allow and to support continued use of the inventive lens in place on the eye. The epithelial cells may (often in the form of a discrete layer) be placed on at least a portion of the anterior surface of a lens. In some variations, all of the anterior surface will be so-covered. In one variation discussed below, an epithelial layer will extend beyond the periphery of the lens core and optionally the lens be carried in a biodegradable carrier that is used during placement in the eye and later disappears.
- The described lens may be placed on a host eye from which at least a major portion of the native epithelium on that cornea, has been removed. Preferably in this variation, substantially all of the epithelium has been removed from the region upon which the inventive lens will be sited. The lens may also be placed beneath a layer of epithelium lifted from the eye surface during the procedure of introducing the lens onto the anterior surface of the host cornea or in other instances beneath the surface of the host cornea. The described lens may be used variously to correct refraction (because of its shape) or it may be used simply to provide a source of infused medication to the eye.
- The donor lenticule or lens core may be obtained from other human (allogeneic) or foreign tissue (xenogenic) sources. Appropriate xenogenic sources include rabbit, bovine, porcine, or guinea pig corneal tissue. The ocular lens cores may also come from transgenic corneal tissue or corneal tissue grown in vitro. In many instances, it is desired that the architecture of the corneal layers in the donated tissue, the normal corneal tissue matrix, e.g., the connective tissue or the stroma, be substantially preserved. The “corneal tissue matrix” is made up of thin layers of collagen fibrils. The term “donor corneal tissue”, as used here, is meant to include donor or harvested corneas or corneal tissue containing the “corneal tissue matrix”. Additionally, in most variations, it is highly desirable to preserve the anterior surface of the donated corneal tissue as found beneath the native epithelium. The donor corneal tissue is not to undergo harsh treatments such as lyophilization, freezing, or other chemical fixation. Nevertheless, it is sometimes desirable to utilize only a portion of the anterior surface of the donor lens, e.g., in those instances where the inventive lens structure is annular in shape.
- The described ocular lens device desirably includes Bowman's membrane, where the donor tissue includes it, to maintain the native structure of human epithelium. Again, it is highly desirable to harvest from donor sources in such a way that the native anterior surface below the epithelium is preserved. I have found that these native structures have a superior ability, particularly after the revitalization steps discussed below, to support and to maintain the replaced epithelium also discussed below. The clarity of the inventive tissue lens core handled in such a way generally will be at least 85%, preferably between 75%-100%, and most preferably at least 90%, of that of human corneal tissue of corresponding thickness.
- The overall diameter of my lens is functionally appropriate to perform the desired correction, and generally is less than about 25 mm and more preferably is between 10 and 15 mm. The thickness of the resulting lens is, again, functionally appropriate to perform the desired correction, e.g., generally less than 300 μm, more preferably between 5-100 μm.
- As shown in
FIG. 3B , a lens core (316) for myopic patients is formed, preferably using the procedures discussed below, in such a way that a generally circular region (318) in the center is flattened in its anterior curvature. In correction of aphakia, a lens such as is shown inFIG. 3C is formed having a comparatively thicker center (322) and a thinner perimeter (324). In general, the shapes discussed here are similar to those found in the so-called “soft” contact lenses and instruction may be had from that technology relating to the overall form of the lenses selected for correcting specific ocular maladies. - As shown in
FIGS. 3D and 3E , the lens may also be used to correct presbyopia. In particular, to treat presbyopia, the lens (330) is also provided with an generally opaque annular region (332) adjacent the center of the device. The open center (334) preferably has plano-lens characteristics and an effective diameter of less than about 1.5 mm, preferably between about 0.5-1.5 mm, and most preferably between 0.75 mm and 1.75 mm. The diameter of that open center (334) or central area or “pinhole” is generally formed and selected to be less than the pupillary diameter of the host eye in daylight. This creates a “pinhole” effect, thereby lengthening the overall effective focal length of the eye and minimizing the need for the eye to accommodate. Other bifocal lens designs can also be incorporated, e.g., concentric rings, segmented or sectors of the annular region or ring, or progressive diffractive. -
FIG. 3E shows a side, cross-sectional view of my lens (330) shown inFIG. 3D , adjacent the anterior surface of a cornea (344) to illustrate certain features of this variation. The outer diameter (336) of the opaque annular ring (332) is generally selected so that it is smaller than the diameter (338) of the pupil (340) in the iris (342) in low light conditions. In this way, the eye's cornea and lens and the inventive lens cooperate in such a way that incident light passes both though the center of the opaque ring (334), but more importantly, around the periphery of the opaque ring (332), to allow corrected sight during low light conditions. - The annular ring (332) may be situated on the lens core either by placement of a suitable dye, i.e., by “tattooing”, or by placement of a substantially opaque biocompatible member of, e.g., Dacron mesh or the like, on the posterior surface to filter light rays. Other placements of the annular ring (332) may be envisioned, e.g., on the anterior surface of the inventive lens. The annular ring (332) itself preferably is quite opaque, e.g., passing less than about 80% of incident visible light, but may be chosen in such a way to be less opaque or to correct other maladies such as colorblindness by shifting an incident color into a visible range by color refraction or the like.
- As is shown in
FIGS. 3F (in front view) and 3G (in cross section), another variation of the lens device (346) includes a core lens (348) as discussed above but having an epithelial layer (352) that extends beyond the periphery (350) of that lens core (348). The method for producing the variation (346) with an extra-periphery epithelial layer (352) is similar to the method described elsewhere herein except that the lens core (348) is desirably placed in a carrier (354 inFIG. 3H )) having a shape generally conforming to the anterior surface of the donor core lens (348). - The carrier (354), as shown in
FIG. 3H , desirably serves several functions. First, it provides a substrate for growth of the epithelial layer (352) prior to the time that the core lens (348) is placed on that epithelial layer (352). This extra surface beyond the periphery of the core lens (348) provides support for the otherwise fragile epithelial layer (352). The carrier (354) may be placed in or formed in a properly shaped receptacle that, in turn, provides support for the fragile carrier (354) during the steps of growing an epithelial layer (352). - The combination (356) of carrier (354), epithelial layer (352)—whether the epithelial layer (352) extends beyond the periphery of the core lens (348) or not, e.g., the epithelial layer (352) is situated only on some or all of the core lens (348)—and core lens (348) placed on that epithelial layer (352), as shown in
FIG. 3H , is another variation of the invention. The construct (356) shown inFIG. 3H may, upon proper choice of materials for the carrier, be placed directly in the host eye thereby providing support for the epithelial layer (352) and core lens (348), as well as optionally, medication or other treatment materials for the eye during initial placement. - When the carrier is used for placement in the eye, the carrier (354) preferably comprises a material meeting two related criteria. First, the material desirably is one that dissolves, erodes, or otherwise shortly clears from the eye to be treated after the combination (356) of the carrier (354), epithelial layer (352), and the donor lens (348) are introduced to that eye. Preferably also, the carrier is of a material that serves as a substrate for a pre-grown epithelial layer. Most desirably, the carrier (354) satisfies both criteria. The carrier (354) may comprise a material such as collagen, gelatin, starch, glucosamine glucans, proteins, carbohydrates, polyanhydrides such as polylactides and polyglycolides, their mixtures and copolymers, polydiaxanone, etc.
- The carrier (354) may also be infused with medication or other treatment material, antiangiogenesis materials or the like.
-
FIGS. 3I and 3J show, respectively, a front view and a side cross sectional view of a lens (360) having a central opening (362) passing through the lens body. Although this lens variation (360) is shown without an epithelial layer, it is within the scope of the invention to so include the layer. - Returning to
FIG. 3A , the donor core lens (300) desirably is obtained after slicing corneal tissue from the donor with a microkeratome to form that lens core (300). The donor lens (300) has a structural surface, the anterior surface of the lens core, which serves as the structural surface of the donor corneal tissue. The lens core anterior surface is harvested preferably to retain the Bowman's membrane (where the donor lens contains one) and epithelium (302). The posterior surface (304) of the resulting lens is generally concave in shape, although it need not be so. The anterior surface of the lens may be shaped via a shaping step which preferably involves the use of an ablative laser, such as an excimer laser, to obtain the necessary power of the lens. Another suitable forming step is high pressure water jet cutting. - Although the order of the process steps outlined below is typical, it should be understood that such steps may be varied as needed to produce the desired result.
- Generally, the lens will first be shaped to an appropriate shape as discussed above. The lens core may then be subjected to processes of sterilization, devitalization, and revitalization. Removal of epithelium (de-epithelialization) and keratocytes (acellularization) from the donor lens will be referred to as “devitalization”. The addition of human epithelium and keratocytes will be referred to as “revitalization”. One desirable method for accomplishing those steps is found just below. Other equivalent methods are known.
- Phosphate buffered saline (PBS) with antibiotics, epithelial cell media, and keratocyte media are solutions used during these processes. The “PBS with antibiotics” solution may contain:
- PBS with Antibiotics
-
- 1. Amphotericin B (ICN Biomedicals) 0.625 μg/ml
- 2. Penicillin (Gibco BRL) 100 IU/ml
- 3. Streptomycin (Gibco BRL) 100 μg/ml
- 4. Phosphate buffered saline (Gibco BRL)
- The composition of the epithelial cell media may include:
- Epithelial Cell Media
-
- 1. Dulbecco's Modified Eagle Media/Ham's F12 media (Gibco BRL) 3:1
- 2. 10% fetal calf serum (Gibco BRL)
- 3. Epidermal growth factor (ICN Biomedicals) 10 ng/ml
- 4. Hydrocortisone (Sigma-Aldrich) 0.4 μg/ml
- 5. Cholera toxin (ICN Biomedicals) 10−10 M
- 6. Adenine (Sigma-Aldrich) 1.8×10−4 M
- 7. Insulin (ICN Biomedicals) 5 μg/ml
- 8. Transferrin (ICN Biomedicals) 5 μg/ml
- 9. Glutamine (Sigma-Aldrich) 2×10 −3 M
- 10. Triiodothyronine (ICN Biomedicals) 2×10 −7 M
- 11. Amphotericin B (ICN Biomedicals) 0.625 μg/ml
- 12. Penicillin (Gibco BRL) 100 IU/ml
- 13. Streptomycin (Gibco BRL) 100 μg/ml
- The composition of the keratocyte media may include:
- Kerat
-
- 1. DMEM
- 2. 10% neonatal calf serum (Gibco BRL)
- 3. Glutamine (Sigma-Aldrich) 2×10−3 M
- 4. Amphotericin B (ICN Biomedicals) 0.625 μg/ml
- After harvesting the lens core from donor corneal tissue and following the shaping step, the lens may be sterilized, for instance, by immersion into 98% glycerol at room temperature. Three weeks of glycerol treatment inactivates intracellular viruses and any bacteria or fungi. Ethylene oxide gas sterilization may also be used, but tends to induce variable damage to stromal tissue.
- De-epithelialization
- I prefer to de-epithelialize the donor lens by placing it in a one molar solution of salt (preferably sodium chloride) at a temperature from 4 to 25° C. After four to eight hours of incubation, the entire epithelial layer generally will split from the corneal stroma and may be easily removed. Thereafter the lens may be washed in a PBS solution with antibiotics to remove salt and cellular material.
- Another method of removing the epithelium is via the use of vacuum. The epithelium may be split from the stroma by means of suction (−100 mm Hg to −450 mm Hg). After fifteen minute to 1 hour, the epithelium typically will separate from the stroma at the basement membrane layer. Thereafter the lens may be washed in a PBS solution with antibiotics to remove salt and cellular material.
- Finally, the donor lens may be de-epithelialized by placing it in sterile PBS with antibiotics for four hours and changing the solution many times. The lens core may then be kept submerged in the PBS solution at 37° C. for one week to produce a split between the epithelium and the stroma. The epithelium may then be removed, e.g., by physically scraping or washing with a liquid stream. Small numbers of lenses may be stripped of epithelium by gentle scraping with forceps.
- Acellularization
- The de-epithelialized lens may be then immersed in a solution of detergent (for example 0.025% to 15% sodium dodecyl sulfate) to wash out the keratocyte cellular material. A detergent will solubilize and wash out the keratinocytic material. This can take place from 1 to 8 hours. Afterward the cellular material can be washed in a buffered solution with antibiotics to remove detergent and cellular material.
- Alternatively, the de-epithelialized lens may be immersed in sterile PBS with antibiotics for an appropriate period, e.g., several weeks, perhaps six weeks to remove native keratocytes. The solution may be changed twice weekly. In some instances, it may not be necessary to remove keratocytes from the donor lens, e.g., when the donor tissue is obtained from a transgenic source and has minimal antigenicity.
- Preparation of Cells
- Human epithelial cells and keratocytes are used in the revitalization process. Epithelial cells may be obtained from a tissue bank, but are preferably obtained from fetal or neonatal tissue. Fetal cells are most preferable, since the properties of fetal tissue minimize scarring during any wound healing process.
- In any event, freshly isolated epithelial cells, obtained by trypsinization of corneal tissue, may be seeded onto a precoated feeder layer of lethally irradiated 3T3 fibroblasts (i.3T3) in epithelial cell media. Cells are cultured and media changed every three days until the cells are 80% confluent, about 7-9 days. Residual i.3T3 are removed with 0.02% EDTA (Sigma-Aldrich) before the epithelial cells are detached using trypsin (ICN Biomedicals). Another method of regenerating epithelium involves culturing autologous epithelial cells on human amniotic membrane as described in Tsai et al. (2000). “Reconstruction of Damaged Corneas by Transplantation of Autologous Limbal Epithelial Cells,” New England Journal of Medicine 343:86-93.
- Keratocytes may be extracted from the remaining stromal tissue. The stroma is washed in PBS, finely minced, and placed in 0.5% collagenase A (ICN Biomedicals) at 37° C. for 16 hours. Keratocytes obtained from this enzyme digest are then serially cultured in keratocyte media. The epithelial cells and keratocytes generated in the revitalization step will be referred to as “replaced” epithelial cells and keratocytes.
- The acellular donor lens core may then be placed on a hydrophilic, polyelectrolyte gel for completion of the re-vitalization. The preferred polyelectrolytes are chondroitin sulfate, hyaluronic acid, and polyacrylamide. Most preferred is polyacrylic acid. The lens is immersed in keratocyte media and incubated with approximately 3×105 keratocytes for 48 hours at 37° C. Approximately the same amount of epithelial cells are then added to the anterior stromal surface. Tissue culture incubation continues for another 48 hours. Keratocyte media is changed every two to three days. Once the epithelium is regenerated, the polyelectrolyte gel draws water out of the lens at a pressure of about 20-30 mm Hg until the original lens dimensions are obtained.
- Replaced epithelium covers at least a portion of the anterior surface of this variation of the inventive lens and replaced keratocytes repopulate the stroma of the lens core after revitalization.
- As noted above, another variation of the lens includes an epithelial layer (352 in
FIG. 3G ) that extends from the periphery of the lens core (348). The same procedure as just outlined may be used to prepare the epithelial cell layer in the carrier (354) prior to placement of the lens core (348) onto the pre-prepared epithelial cell layer. - It may be beneficial in some instances also to incorporate therapeutic agents, growth factors, or immunosuppressive agents into the lens core further to decrease the risk of rejection or remedy disease states.
- One procedure for applying the lens of this invention is depicted in
FIGS. 4A and 4B . During the procedure, the donor lens (300), as shown inFIG. 3A , is placed on a portion of recipient cornea that has been de-epithelialized (308). The result is the placement and construct (312) shown inFIG. 4B . The lens' replaced epithelium and the host epithelium eventually grow to form a continuous, water-tight layer (310). I have found that the inventive lens bonds or adheres to the recipient cornea without sutures or adhesives, but can also be removed without substantial difficulty. - Another placement procedure variation is shown in
FIG. 5 . In this variation, it is preferable to use a core lens that has been only partially revitalized in that the keratocytes have been replaced but the epithelial layer has not. Of course, a core lens that has been partially covered with a seed layer of epithelial cells is also acceptable. In any event, step a. ofFIG. 5 shows a native eye (600) having an epithelial layer (602) and a corneal stroma (604). Step b. ofFIG. 5 shows the placement of a suction device (606) on the anterior surface of the eye (600). The suction device (606) applies a modest vacuum to the epithelial layer (602), e.g., between about −100 mmHg and −450 mmHg, to raise a section of the epithelial layer (602) as shown in step c. This blister (608) typically is filled with a physiologic fluid. Obviously, the suction device (606) has a footprint on the surface of the cornea similar to the size of the lens to be placed on that cornea. Step d. shows the opened epithelial flap (608) and the placement of the lens towards the corneal stromal margin (612) beneath that epithelial flap (608). Step c. ofFIG. 5 shows the finished placement of the lens (610) on the cornea beneath the native epithelial membrane. This procedure has a number of benefits including that of being less traumatic to the surface of the eye than simple removal of the epithelium. - It is also within the scope of the description to use the preparation procedure for the LASEK procedure for the step of exposing the corneal surface for application of the lens. The LASEK procedure is known and, unlike the LASIK procedure, does not involve temporary removal of an anterior flap of corneal tissue with a surgical tool but rather only utilizes an ethanol wash and a temporary withdrawal of the epithelial layer for a laser treatment. Such a preliminary step, the washing with ethanol to perturb the junction between the corneal stroma and the epithelium is adequate to provide a layer of epithelium for temporary movement and insertion of the inventive lens on the corneal surface.
- I have described the structural and physiologic properties and benefits of this donor ocular lens. This manner of description should not, however, be taken as limiting the scope of the disclosure in any way.
Claims (8)
1. A device for separating a living epithelial tissue region from an eye having an anterior corneal surface and an epithelial tissue layer, the device being configured for lifting from the corneal surface, a substantially continuous, living epithelial layer substantially free from corneal tissue and having at least an edge connected to the corneal surface.
2. The device of claim 1 wherein the device is further configured for lifting an epithelial layer comprising an epithelial flap.
3. The device of claim 1 wherein the device is further configured for lifting an epithelial layer of sufficient size for placement of a vision corrective lens on the anterior corneal surface completely beneath the epithelial layer.
4. The device of claim 1 wherein the device comprises a vacuum.
5. A device for separating a living epithelial tissue region from an eye having an anterior corneal surface and an epithelial tissue layer, comprising a device configured for lifting from the corneal surface, a substantially continuous, living epithelial layer substantially free from corneal tissue and having at least an edge connected to the corneal surface, said device further configured to be removed from contact with the corneal surface leaving the living epithelial layer attached.
6. The device of claim 5 wherein the device is further configured for lifing an epithelial layer comprising an epithelial flap.
7. The device of claim 5 wherein the device is further configured for lifting an epithelial layer of sufficient size for placement of a vision corrective lens on the anterior corneal surface completely beneath the epithelial layer.
8. The device of claim 5 wherein the device comprises a vacuum.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/956,511 US20050070942A1 (en) | 2000-07-18 | 2004-10-01 | Device for lifting an epitheleal layer and placing a corrective lens beneath it |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/618,580 US6544286B1 (en) | 2000-07-18 | 2000-07-18 | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
PCT/US2001/022633 WO2002006883A2 (en) | 2000-07-18 | 2001-07-18 | Pre-fabricated corneal tissue lens and method of corneal overlay to correct vision (ii) |
US10/243,121 US6880558B2 (en) | 2000-07-18 | 2002-09-13 | Method of lifting an epithelial layer and placing a corrective lens beneath it |
US10/956,511 US20050070942A1 (en) | 2000-07-18 | 2004-10-01 | Device for lifting an epitheleal layer and placing a corrective lens beneath it |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/618,580 Continuation-In-Part US6544286B1 (en) | 2000-07-18 | 2000-07-18 | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
PCT/US2001/022633 Continuation WO2002006883A2 (en) | 2000-07-18 | 2001-07-18 | Pre-fabricated corneal tissue lens and method of corneal overlay to correct vision (ii) |
US10/243,121 Continuation US6880558B2 (en) | 2000-07-18 | 2002-09-13 | Method of lifting an epithelial layer and placing a corrective lens beneath it |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050070942A1 true US20050070942A1 (en) | 2005-03-31 |
Family
ID=24478269
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/618,580 Expired - Fee Related US6544286B1 (en) | 2000-07-18 | 2000-07-18 | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
US10/243,121 Expired - Fee Related US6880558B2 (en) | 2000-07-18 | 2002-09-13 | Method of lifting an epithelial layer and placing a corrective lens beneath it |
US10/317,714 Abandoned US20030105521A1 (en) | 2000-07-18 | 2002-12-11 | Pre-fabricated corneal tissue lens and method of corneal overlay to correct vision |
US10/956,511 Abandoned US20050070942A1 (en) | 2000-07-18 | 2004-10-01 | Device for lifting an epitheleal layer and placing a corrective lens beneath it |
US11/030,421 Abandoned US20050124982A1 (en) | 2000-07-18 | 2005-01-05 | Method of producing an epithelial flap (II) |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/618,580 Expired - Fee Related US6544286B1 (en) | 2000-07-18 | 2000-07-18 | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
US10/243,121 Expired - Fee Related US6880558B2 (en) | 2000-07-18 | 2002-09-13 | Method of lifting an epithelial layer and placing a corrective lens beneath it |
US10/317,714 Abandoned US20030105521A1 (en) | 2000-07-18 | 2002-12-11 | Pre-fabricated corneal tissue lens and method of corneal overlay to correct vision |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/030,421 Abandoned US20050124982A1 (en) | 2000-07-18 | 2005-01-05 | Method of producing an epithelial flap (II) |
Country Status (10)
Country | Link |
---|---|
US (5) | US6544286B1 (en) |
EP (1) | EP1301223A2 (en) |
JP (1) | JP2004504627A (en) |
KR (1) | KR20030045779A (en) |
CN (1) | CN1243573C (en) |
AU (2) | AU2001278947B2 (en) |
CA (1) | CA2418306A1 (en) |
IL (2) | IL153969A0 (en) |
MX (1) | MXPA03000511A (en) |
WO (1) | WO2002006883A2 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050080484A1 (en) * | 2002-09-13 | 2005-04-14 | Ocular Sciences, Inc. | Devices and methods for improving vision |
US20050288696A1 (en) * | 2001-07-23 | 2005-12-29 | Pallikaris Ioannis G | Device for separating the epithelial layer from the surface of the cornea of an eye |
US20060134170A1 (en) * | 2004-08-13 | 2006-06-22 | May Griffith | Vision enhancing ophthalmic devices and related methods and compositions |
US20060203189A1 (en) * | 2000-11-10 | 2006-09-14 | Coopervision, Inc. | Junctionless Ophthalmic Lenses and Methods for Making Same |
US20070182920A1 (en) * | 2006-02-08 | 2007-08-09 | Coopervision, Inc. | Corneal Onlays and Related Methods |
US20070239184A1 (en) * | 2006-04-10 | 2007-10-11 | Markus Gaeckle | Corneal epithelial pocket formation systems, components and methods |
US20100087920A1 (en) * | 2008-10-07 | 2010-04-08 | Forsight Labs, Llc | Corneal Onlay Lenses and Related Methods for Improving Vision of Presbyopic Patients |
US9555111B2 (en) | 2012-03-29 | 2017-01-31 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US10278920B1 (en) * | 2014-05-12 | 2019-05-07 | Gholam A. Peyman | Drug delivery implant and a method using the same |
US10564447B2 (en) | 2013-11-20 | 2020-02-18 | Iwane Mitsui | Contact lens for corrected-cornea crosslinking, corrected-cornea crosslinking method, and ring-shaped contact lens |
US10575986B2 (en) | 2012-03-29 | 2020-03-03 | Cxl Ophthalmics, Llc | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
US11565023B2 (en) * | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000052516A2 (en) | 1999-03-01 | 2000-09-08 | Boston Innovative Optics, Inc. | System and method for increasing the depth of focus of the human eye |
US6544286B1 (en) * | 2000-07-18 | 2003-04-08 | Tissue Engineering Refraction, Inc. | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
WO2002021965A1 (en) | 2000-09-12 | 2002-03-21 | Anamed, Inc. | System for packaging and handling an implant and method of use |
US8668735B2 (en) | 2000-09-12 | 2014-03-11 | Revision Optics, Inc. | Corneal implant storage and delivery devices |
US20070265650A1 (en) * | 2001-07-23 | 2007-11-15 | Ioannis Pallikaris | Device for separating the epithelial layer from the surface of the cornea of an eye |
US7156859B2 (en) * | 2001-07-23 | 2007-01-02 | Fos Holding S.A. | Device for separating the epithelium layer from the surface of the cornea of an eye |
MXPA04006954A (en) | 2002-01-17 | 2005-03-23 | Perez Edward | Methods for producing epithelial flaps on the cornea and for placement of ocular devices and lenses beneath an epithelial flap or membrane, epithelial delaminating devices, and structures of epithelium and ocular devices and lenses. |
CA2508689A1 (en) * | 2002-12-10 | 2004-06-24 | Sightrate B.V. | Disposable separator for separating the epithelium layer from the cornea of an eye |
US20040260321A1 (en) * | 2002-12-19 | 2004-12-23 | Ming-Kok Tai | Apparatus and method for separating the epithelium layer from the cornea of an eye without corneal pre-applanation |
US7628810B2 (en) | 2003-05-28 | 2009-12-08 | Acufocus, Inc. | Mask configured to maintain nutrient transport without producing visible diffraction patterns |
US20050046794A1 (en) | 2003-06-17 | 2005-03-03 | Silvestrini Thomas A. | Method and apparatus for aligning a mask with the visual axis of an eye |
WO2005020792A2 (en) * | 2003-08-21 | 2005-03-10 | Revision Optics, Inc. | Method for keratophakia surgery |
JP2007503902A (en) * | 2003-09-05 | 2007-03-01 | サイトレイト ビー.ブイ. | Corneal epithelium separation device |
US7025455B2 (en) * | 2003-12-19 | 2006-04-11 | J&J Vision Care, Inc. | Multifocal contact lenses having a pinhole |
US20050213030A1 (en) * | 2004-02-25 | 2005-09-29 | Meyers William E | Corrective lens for corneal reshaping and method of determining the design of the corrective lens |
US20080262610A1 (en) * | 2007-04-20 | 2008-10-23 | Alan Lang | Biomechanical design of intracorneal inlays |
US7776086B2 (en) * | 2004-04-30 | 2010-08-17 | Revision Optics, Inc. | Aspherical corneal implant |
US10835371B2 (en) | 2004-04-30 | 2020-11-17 | Rvo 2.0, Inc. | Small diameter corneal inlay methods |
US8057541B2 (en) | 2006-02-24 | 2011-11-15 | Revision Optics, Inc. | Method of using small diameter intracorneal inlays to treat visual impairment |
US6945971B1 (en) * | 2004-07-19 | 2005-09-20 | Gwon Arlene E | Controlled ocular lens regeneration |
US7976577B2 (en) | 2005-04-14 | 2011-07-12 | Acufocus, Inc. | Corneal optic formed of degradation resistant polymer |
US9107982B2 (en) | 2005-11-09 | 2015-08-18 | Paul Hong-Dze Chen | Cultured tissue transplant device |
US8158141B2 (en) * | 2005-11-09 | 2012-04-17 | Paul Hong-Dze Chen | Cell transplant device for treatment of corneal wound |
US10555805B2 (en) | 2006-02-24 | 2020-02-11 | Rvo 2.0, Inc. | Anterior corneal shapes and methods of providing the shapes |
MX2008011680A (en) | 2006-03-16 | 2008-12-10 | Daxer Albert | Structural member. |
US20070255401A1 (en) * | 2006-05-01 | 2007-11-01 | Revision Optics, Inc. | Design of Inlays With Intrinsic Diopter Power |
EP2019646A4 (en) * | 2006-05-04 | 2013-12-04 | Herbert Kaufman | Method, device, and system for delivery of therapeutic agents to the eye |
AU2007253255A1 (en) | 2006-05-23 | 2007-11-29 | Albert Daxer | Corneal implant and method for correction of impaired vision in the human eye |
US20100215720A1 (en) * | 2006-08-08 | 2010-08-26 | Fundacion Inasmet | Implantable optical system, method for developing it and applications |
WO2008096821A1 (en) * | 2007-02-08 | 2008-08-14 | Kaneka Corporation | Injector for eye |
US9549848B2 (en) | 2007-03-28 | 2017-01-24 | Revision Optics, Inc. | Corneal implant inserters and methods of use |
US8162953B2 (en) * | 2007-03-28 | 2012-04-24 | Revision Optics, Inc. | Insertion system for corneal implants |
US9271828B2 (en) | 2007-03-28 | 2016-03-01 | Revision Optics, Inc. | Corneal implant retaining devices and methods of use |
US9943401B2 (en) | 2008-04-04 | 2018-04-17 | Eugene de Juan, Jr. | Therapeutic device for pain management and vision |
US9125735B2 (en) * | 2008-04-04 | 2015-09-08 | Forsight Labs, Llc | Method of correcting vision using corneal onlays |
AU2009231636B2 (en) | 2008-04-04 | 2014-07-24 | Revision Optics, Inc. | Corneal inlay design and methods of correcting vision |
US9539143B2 (en) | 2008-04-04 | 2017-01-10 | Revision Optics, Inc. | Methods of correcting vision |
US20100198348A1 (en) * | 2009-01-30 | 2010-08-05 | Hiles Michael C | Biomaterials with modified optical character and methods for preparing and using same |
KR101029887B1 (en) * | 2009-03-04 | 2011-04-18 | 서울대학교산학협력단 | Method to process porcine cornea for decellularization |
CA2770735C (en) | 2009-08-13 | 2017-07-18 | Acufocus, Inc. | Masked intraocular implants and lenses |
US10004593B2 (en) | 2009-08-13 | 2018-06-26 | Acufocus, Inc. | Intraocular lens with elastic mask |
US9427311B2 (en) | 2009-08-13 | 2016-08-30 | Acufocus, Inc. | Corneal inlay with nutrient transport structures |
US8591025B1 (en) | 2012-09-11 | 2013-11-26 | Nexisvision, Inc. | Eye covering and refractive correction methods for LASIK and other applications |
WO2011050365A1 (en) | 2009-10-23 | 2011-04-28 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
ES2649890T3 (en) | 2009-10-23 | 2018-01-16 | Nexisvision, Inc. | Corneal enervation for the treatment of eye pain |
USD656526S1 (en) | 2009-11-10 | 2012-03-27 | Acufocus, Inc. | Ocular mask |
US8469948B2 (en) | 2010-08-23 | 2013-06-25 | Revision Optics, Inc. | Methods and devices for forming corneal channels |
CN103281995B (en) | 2010-10-25 | 2016-04-06 | 内希斯视觉股份有限公司 | Identify the method and apparatus for the eyes covering of vision |
JP2014514613A (en) | 2011-04-28 | 2014-06-19 | ネクシスビジョン, インコーポレイテッド | Ocular covering and refractive correction methods and devices with improved tear flow, comfort and / or applicability |
WO2014210186A2 (en) | 2013-06-26 | 2014-12-31 | Nexisvision, Inc. | Contact lenses for refractive correction |
RU2619654C2 (en) | 2011-10-21 | 2017-05-17 | Ревижн Оптикс, Инк. | Device for cornea implants storage and delivery |
CA2857306C (en) | 2011-12-02 | 2017-07-25 | Acufocus, Inc. | Ocular mask having selective spectral transmission |
WO2013111121A1 (en) * | 2012-01-27 | 2013-08-01 | Ecole Polytechnique Federale De Lausanne (Epfl) | Device for the transplantation of cells in suspension |
WO2013184239A1 (en) | 2012-04-20 | 2013-12-12 | Nexisvision, Inc. | Contact lenses for refractive correction |
US9465233B2 (en) | 2012-04-20 | 2016-10-11 | Nexisvision, Inc. | Bimodular contact lenses |
US9974646B2 (en) | 2012-09-05 | 2018-05-22 | University Of Miami | Keratoprosthesis, and system and method of corneal repair using same |
US9204962B2 (en) | 2013-03-13 | 2015-12-08 | Acufocus, Inc. | In situ adjustable optical mask |
US10092393B2 (en) | 2013-03-14 | 2018-10-09 | Allotex, Inc. | Corneal implant systems and methods |
US9427922B2 (en) | 2013-03-14 | 2016-08-30 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
US9668916B2 (en) | 2013-11-04 | 2017-06-06 | Vance M. Thompson | Conjunctival cover and methods therefor |
US9341864B2 (en) | 2013-11-15 | 2016-05-17 | Nexisvision, Inc. | Contact lenses having a reinforcing scaffold |
WO2015116559A1 (en) | 2014-01-29 | 2015-08-06 | Nexisvision, Inc. | Multifocal bimodulus contact lenses |
US20170189166A1 (en) * | 2014-05-27 | 2017-07-06 | Revision Optics, Inc. | Corneal implants and methods of manufacturing |
US10945832B2 (en) | 2014-09-22 | 2021-03-16 | Onpoint Vision, Inc. | Intraocular pseudophakic contact lens with mechanism for securing by anterior leaflet of capsular wall and related system and method |
US10159562B2 (en) | 2014-09-22 | 2018-12-25 | Kevin J. Cady | Intraocular pseudophakic contact lenses and related systems and methods |
US11938018B2 (en) | 2014-09-22 | 2024-03-26 | Onpoint Vision, Inc. | Intraocular pseudophakic contact lens (IOPCL) for treating age-related macular degeneration (AMD) or other eye disorders |
US11109957B2 (en) | 2014-09-22 | 2021-09-07 | Onpoint Vision, Inc. | Intraocular pseudophakic contact lens with mechanism for securing by anterior leaflet of capsular wall and related system and method |
US10299910B2 (en) | 2014-09-22 | 2019-05-28 | Kevin J. Cady | Intraocular pseudophakic contact lens with mechanism for securing by anterior leaflet of capsular wall and related system and method |
EP3220859B8 (en) | 2014-11-19 | 2020-06-10 | AcuFocus, Inc. | Fracturable mask for treating presbyopia |
US9869883B2 (en) | 2015-03-11 | 2018-01-16 | Vance M. Thompson | Tear shaping for refractive correction |
WO2016144404A1 (en) | 2015-03-12 | 2016-09-15 | Revision Optics, Inc. | Methods of correcting vision |
US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
RU2578086C1 (en) * | 2015-09-02 | 2016-03-20 | Аслан Рамазанович Хурай | Method of ophthalmic surgical operations using autograft |
EP3359987B1 (en) | 2015-10-05 | 2024-02-28 | AcuFocus, Inc. | Methods of molding intraocular lenses |
CA3005891C (en) | 2015-11-24 | 2023-12-12 | Acufocus, Inc. | Toric small aperture intraocular lens with extended depth of focus |
CN105288736B (en) * | 2015-11-24 | 2016-11-16 | 北京清源伟业生物组织工程科技有限公司 | Acellular dermal matrix cornea and the preparation method of ocular tissue renovation material |
HUE055940T2 (en) * | 2016-09-12 | 2022-01-28 | Gebauer Klopotek Patent Verwaltungs Ug | Lenticules for intrastromal corneal implantation |
US10353220B2 (en) | 2016-10-17 | 2019-07-16 | Vance M. Thompson | Tear shaping for refractive correction |
CN107233144A (en) * | 2017-05-31 | 2017-10-10 | 中山大学中山眼科中心 | Go application of the cell corneal stroma lens in treatment ophthalmology disease |
AU2018282219A1 (en) | 2017-06-05 | 2019-12-19 | Corneagen Inc. | Systems and methods for corneal transplants |
US10678067B2 (en) | 2018-04-06 | 2020-06-09 | Vance M. Thompson | Tear shaping for refractive correction |
WO2019217471A1 (en) | 2018-05-09 | 2019-11-14 | Acufocus, Inc. | Intraocular implant with removable optic |
US20200085564A1 (en) | 2018-09-18 | 2020-03-19 | Vance M. Thompson | Structures and methods for tear shaping for refractive correction |
WO2021048853A1 (en) * | 2019-09-12 | 2021-03-18 | Corneat Vision Ltd. | Graft patch for the treatment of myopia and ophthalmic conditions |
EP4031069A1 (en) | 2019-09-20 | 2022-07-27 | Niios-USA Inc. | Donor overlay for treatment or alleviation of anterior corneal disorders |
Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4346482A (en) * | 1981-01-22 | 1982-08-31 | Tennant Jerald L | Living contact lens |
US4440918A (en) * | 1982-01-18 | 1984-04-03 | Minnesota Mining And Manufacturing Company | Contact lens containing a fluorinated telechelic polyether |
US4607617A (en) * | 1980-08-05 | 1986-08-26 | Choyce David P | Apparatus and method for improving eyesight |
US4646720A (en) * | 1985-03-12 | 1987-03-03 | Peyman Gholam A | Optical assembly permanently attached to the cornea |
US4662881A (en) * | 1986-01-21 | 1987-05-05 | Nordan Lee T | Epikeratophakia process |
US4676790A (en) * | 1985-09-25 | 1987-06-30 | Kern Seymour P | Method of manufacture and implantation of corneal inlays |
US4693715A (en) * | 1986-06-19 | 1987-09-15 | Abel Robert Jr | Artificial cornea |
US4715858A (en) * | 1986-07-25 | 1987-12-29 | Lindstrom Richard L | Epicorneal lens |
US4793344A (en) * | 1987-11-02 | 1988-12-27 | Recore, Inc. | Method for preparing corneal donor tissue for refractive eye surgery |
US4818801A (en) * | 1982-01-18 | 1989-04-04 | Minnesota Mining And Manufacturing Company | Ophthalmic device comprising a polymer of a telechelic perfluoropolyether |
US5057578A (en) * | 1990-04-10 | 1991-10-15 | E. I. Du Pont De Nemours And Company | Silicone-containing block copolymers and macromonomers |
US5171318A (en) * | 1987-11-09 | 1992-12-15 | Chiron Ophthalmics, Inc. | Treated corneal prosthetic device |
US5192316A (en) * | 1988-02-16 | 1993-03-09 | Allergan, Inc. | Ocular device |
US5213720A (en) * | 1986-10-16 | 1993-05-25 | Cbs Lens, A California General Partnership | Method of fabricating a collagen-hydrogel |
US5300116A (en) * | 1992-08-05 | 1994-04-05 | Lions Eye Institute Of Western Australia | Keratoprosthesis |
US5314960A (en) * | 1990-04-10 | 1994-05-24 | Permeable Technologies, Inc. | Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment |
US5371147A (en) * | 1990-10-11 | 1994-12-06 | Permeable Technologies, Inc. | Silicone-containing acrylic star polymers, block copolymers and macromonomers |
US5374515A (en) * | 1992-11-13 | 1994-12-20 | Organogenesis, Inc. | In vitro cornea equivalent model |
US5395385A (en) * | 1989-12-14 | 1995-03-07 | Corneal Contouring, Inc. | Apparatus for surgically re-profiling the cornea |
US5496339A (en) * | 1994-05-17 | 1996-03-05 | Koepnick; Russell G. | Universal automated keratectomy apparatus and method |
US5632773A (en) * | 1994-05-03 | 1997-05-27 | Allergan, Inc. | Biostable corneal implants |
US5713957A (en) * | 1993-11-19 | 1998-02-03 | Ciba Vision Corporation | Corneal onlays |
US5777719A (en) * | 1996-12-23 | 1998-07-07 | University Of Rochester | Method and apparatus for improving vision and the resolution of retinal images |
US5786434A (en) * | 1995-09-12 | 1998-07-28 | Menicon Co., Ltd. | Water-absorptive soft contact lens material and contact lens made thereof |
US5827641A (en) * | 1992-11-13 | 1998-10-27 | Parenteau; Nancy L. | In vitro cornea equivalent model |
US5919185A (en) * | 1997-04-25 | 1999-07-06 | Peyman; Gholam A. | Universal implant blank for modifying corneal curvature and methods of modifying corneal curvature therewith |
US5994133A (en) * | 1995-04-04 | 1999-11-30 | Novartis Ag | Cell growth substrate polymer |
US6030398A (en) * | 1997-05-30 | 2000-02-29 | Summit Technology, Inc. | Surgical microtomes |
US6036683A (en) * | 1997-01-02 | 2000-03-14 | G. Rodenstock Instruments Gmbh | Process and apparatus for changing the curvature of the cornea |
US6079417A (en) * | 1999-03-23 | 2000-06-27 | Fugo; Richard J. | Method of altering the shape of the cornea of the eye |
US6176580B1 (en) * | 1999-04-02 | 2001-01-23 | Johnson & Johnson Vision Care, Inc. | Method of designing and fitting contact lenses taking into account material properties of the lenses |
US6187053B1 (en) * | 1996-11-16 | 2001-02-13 | Will Minuth | Process for producing a natural implant |
US6225367B1 (en) * | 1998-09-15 | 2001-05-01 | Novartis Ag | Polymers |
US6228113B1 (en) * | 2000-01-10 | 2001-05-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Intracorneal astigmatic onlay |
US6280469B1 (en) * | 1999-05-11 | 2001-08-28 | Mark A. Terry | Implantable iris device for the eye, and method of installing same |
US6280435B1 (en) * | 1998-03-04 | 2001-08-28 | Visx, Incorporated | Method and systems for laser treatment of presbyopia using offset imaging |
US6391055B1 (en) * | 1996-11-13 | 2002-05-21 | Menicon Co., Ltd. | Artificial cornea |
US20030018348A1 (en) * | 2001-07-23 | 2003-01-23 | Ioannis Pallikaris | Device for separating the epithelium layer from the surface of the cornea of an eye |
US6544286B1 (en) * | 2000-07-18 | 2003-04-08 | Tissue Engineering Refraction, Inc. | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
US6551307B2 (en) * | 2001-03-23 | 2003-04-22 | Gholam A. Peyman | Vision correction using intrastromal pocket and flap |
US6623497B1 (en) * | 1998-08-12 | 2003-09-23 | Vladimir Feingold | Keratome without applanator |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4412359A (en) * | 1982-04-26 | 1983-11-01 | Myers William D | Posterior chamber lens implant |
FR2541501B1 (en) * | 1983-02-22 | 1985-08-02 | Ceraver | PROCESS FOR FIXING A TAPERED METAL SLEEVE ON A JOINT OF COMPOSITE MATERIAL |
US4838266A (en) * | 1986-09-08 | 1989-06-13 | Koziol Jeffrey E | Lens shaping device using a laser attenuator |
US5472702A (en) * | 1987-08-26 | 1995-12-05 | United States Surgical Corporation | Sterilization of growth factors |
US5964775A (en) * | 1993-10-12 | 1999-10-12 | New Jersey Institute Of Technology | Method and device for corneal shaping and refractive correction |
US5833701A (en) * | 1994-09-12 | 1998-11-10 | Medjet, Inc. | Procedure and device for corrective and therapeutic eye treatment |
WO2003009789A1 (en) | 2001-07-23 | 2003-02-06 | Fos Holding S.A. | Device for separating the epithelium layer from the surface of the cornea of an eye |
-
2000
- 2000-07-18 US US09/618,580 patent/US6544286B1/en not_active Expired - Fee Related
-
2001
- 2001-07-18 IL IL15396901A patent/IL153969A0/en active IP Right Grant
- 2001-07-18 JP JP2002512733A patent/JP2004504627A/en not_active Withdrawn
- 2001-07-18 MX MXPA03000511A patent/MXPA03000511A/en active IP Right Grant
- 2001-07-18 KR KR10-2003-7000819A patent/KR20030045779A/en not_active Application Discontinuation
- 2001-07-18 EP EP01957178A patent/EP1301223A2/en not_active Withdrawn
- 2001-07-18 CN CNB018158285A patent/CN1243573C/en not_active Expired - Fee Related
- 2001-07-18 CA CA002418306A patent/CA2418306A1/en not_active Abandoned
- 2001-07-18 AU AU2001278947A patent/AU2001278947B2/en not_active Ceased
- 2001-07-18 AU AU7894701A patent/AU7894701A/en active Pending
- 2001-07-18 WO PCT/US2001/022633 patent/WO2002006883A2/en active Application Filing
-
2002
- 2002-09-13 US US10/243,121 patent/US6880558B2/en not_active Expired - Fee Related
- 2002-12-11 US US10/317,714 patent/US20030105521A1/en not_active Abandoned
-
2003
- 2003-01-15 IL IL153969A patent/IL153969A/en not_active IP Right Cessation
-
2004
- 2004-10-01 US US10/956,511 patent/US20050070942A1/en not_active Abandoned
-
2005
- 2005-01-05 US US11/030,421 patent/US20050124982A1/en not_active Abandoned
Patent Citations (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4607617A (en) * | 1980-08-05 | 1986-08-26 | Choyce David P | Apparatus and method for improving eyesight |
US4346482A (en) * | 1981-01-22 | 1982-08-31 | Tennant Jerald L | Living contact lens |
US4818801A (en) * | 1982-01-18 | 1989-04-04 | Minnesota Mining And Manufacturing Company | Ophthalmic device comprising a polymer of a telechelic perfluoropolyether |
US4440918A (en) * | 1982-01-18 | 1984-04-03 | Minnesota Mining And Manufacturing Company | Contact lens containing a fluorinated telechelic polyether |
US4646720A (en) * | 1985-03-12 | 1987-03-03 | Peyman Gholam A | Optical assembly permanently attached to the cornea |
US4676790A (en) * | 1985-09-25 | 1987-06-30 | Kern Seymour P | Method of manufacture and implantation of corneal inlays |
US4662881A (en) * | 1986-01-21 | 1987-05-05 | Nordan Lee T | Epikeratophakia process |
US4693715A (en) * | 1986-06-19 | 1987-09-15 | Abel Robert Jr | Artificial cornea |
US4715858A (en) * | 1986-07-25 | 1987-12-29 | Lindstrom Richard L | Epicorneal lens |
US5716633A (en) * | 1986-10-16 | 1998-02-10 | Cbs Lens, A California General Partnership | Collagen-hydrogel for promoting epithelial cell growth and regeneration of the stroma and artificial lens using the same |
US5522888A (en) * | 1986-10-16 | 1996-06-04 | Cbs Lens, A California General Partnership | Collagen-hydrogel for promoting epithelial cell growth and regeneration of the stroma |
US5213720A (en) * | 1986-10-16 | 1993-05-25 | Cbs Lens, A California General Partnership | Method of fabricating a collagen-hydrogel |
US4793344A (en) * | 1987-11-02 | 1988-12-27 | Recore, Inc. | Method for preparing corneal donor tissue for refractive eye surgery |
US5171318A (en) * | 1987-11-09 | 1992-12-15 | Chiron Ophthalmics, Inc. | Treated corneal prosthetic device |
US5192316A (en) * | 1988-02-16 | 1993-03-09 | Allergan, Inc. | Ocular device |
US5395385A (en) * | 1989-12-14 | 1995-03-07 | Corneal Contouring, Inc. | Apparatus for surgically re-profiling the cornea |
US5314960A (en) * | 1990-04-10 | 1994-05-24 | Permeable Technologies, Inc. | Silicone-containing polymers, oxygen permeable hydrophilic contact lenses and methods for making these lenses and treating patients with visual impairment |
US5057578A (en) * | 1990-04-10 | 1991-10-15 | E. I. Du Pont De Nemours And Company | Silicone-containing block copolymers and macromonomers |
US5371147A (en) * | 1990-10-11 | 1994-12-06 | Permeable Technologies, Inc. | Silicone-containing acrylic star polymers, block copolymers and macromonomers |
US5300116A (en) * | 1992-08-05 | 1994-04-05 | Lions Eye Institute Of Western Australia | Keratoprosthesis |
US5458819A (en) * | 1992-08-05 | 1995-10-17 | Lions Eye Institute Of Western Australia, Incorporated | Method of producing a keratoprosthesis |
US5827641A (en) * | 1992-11-13 | 1998-10-27 | Parenteau; Nancy L. | In vitro cornea equivalent model |
US5374515A (en) * | 1992-11-13 | 1994-12-20 | Organogenesis, Inc. | In vitro cornea equivalent model |
US5713957A (en) * | 1993-11-19 | 1998-02-03 | Ciba Vision Corporation | Corneal onlays |
US5632773A (en) * | 1994-05-03 | 1997-05-27 | Allergan, Inc. | Biostable corneal implants |
US5496339A (en) * | 1994-05-17 | 1996-03-05 | Koepnick; Russell G. | Universal automated keratectomy apparatus and method |
US5994133A (en) * | 1995-04-04 | 1999-11-30 | Novartis Ag | Cell growth substrate polymer |
US5786434A (en) * | 1995-09-12 | 1998-07-28 | Menicon Co., Ltd. | Water-absorptive soft contact lens material and contact lens made thereof |
US6391055B1 (en) * | 1996-11-13 | 2002-05-21 | Menicon Co., Ltd. | Artificial cornea |
US6187053B1 (en) * | 1996-11-16 | 2001-02-13 | Will Minuth | Process for producing a natural implant |
US5777719A (en) * | 1996-12-23 | 1998-07-07 | University Of Rochester | Method and apparatus for improving vision and the resolution of retinal images |
US6036683A (en) * | 1997-01-02 | 2000-03-14 | G. Rodenstock Instruments Gmbh | Process and apparatus for changing the curvature of the cornea |
US5919185A (en) * | 1997-04-25 | 1999-07-06 | Peyman; Gholam A. | Universal implant blank for modifying corneal curvature and methods of modifying corneal curvature therewith |
US6099541A (en) * | 1997-05-30 | 2000-08-08 | Summit Technology, Inc. | Surgical microtomes |
US6030398A (en) * | 1997-05-30 | 2000-02-29 | Summit Technology, Inc. | Surgical microtomes |
US6280435B1 (en) * | 1998-03-04 | 2001-08-28 | Visx, Incorporated | Method and systems for laser treatment of presbyopia using offset imaging |
US6623497B1 (en) * | 1998-08-12 | 2003-09-23 | Vladimir Feingold | Keratome without applanator |
US6225367B1 (en) * | 1998-09-15 | 2001-05-01 | Novartis Ag | Polymers |
US6079417A (en) * | 1999-03-23 | 2000-06-27 | Fugo; Richard J. | Method of altering the shape of the cornea of the eye |
US6176580B1 (en) * | 1999-04-02 | 2001-01-23 | Johnson & Johnson Vision Care, Inc. | Method of designing and fitting contact lenses taking into account material properties of the lenses |
US6280469B1 (en) * | 1999-05-11 | 2001-08-28 | Mark A. Terry | Implantable iris device for the eye, and method of installing same |
US6228113B1 (en) * | 2000-01-10 | 2001-05-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Intracorneal astigmatic onlay |
US6544286B1 (en) * | 2000-07-18 | 2003-04-08 | Tissue Engineering Refraction, Inc. | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
US20030105521A1 (en) * | 2000-07-18 | 2003-06-05 | Edward Perez | Pre-fabricated corneal tissue lens and method of corneal overlay to correct vision |
US6880558B2 (en) * | 2000-07-18 | 2005-04-19 | Tissue Engineering Refractions, Inc. | Method of lifting an epithelial layer and placing a corrective lens beneath it |
US6551307B2 (en) * | 2001-03-23 | 2003-04-22 | Gholam A. Peyman | Vision correction using intrastromal pocket and flap |
US20030018348A1 (en) * | 2001-07-23 | 2003-01-23 | Ioannis Pallikaris | Device for separating the epithelium layer from the surface of the cornea of an eye |
US20030018347A1 (en) * | 2001-07-23 | 2003-01-23 | Ioannis Pallikaris | Device for separating the epithelium layer from the surface of the cornea of an eye |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060203189A1 (en) * | 2000-11-10 | 2006-09-14 | Coopervision, Inc. | Junctionless Ophthalmic Lenses and Methods for Making Same |
US7828431B2 (en) * | 2000-11-10 | 2010-11-09 | Coopervision International Holding Company, Lp | Junctionless ophthalmic lenses and methods for making same |
US20050288696A1 (en) * | 2001-07-23 | 2005-12-29 | Pallikaris Ioannis G | Device for separating the epithelial layer from the surface of the cornea of an eye |
US20050080484A1 (en) * | 2002-09-13 | 2005-04-14 | Ocular Sciences, Inc. | Devices and methods for improving vision |
US20060241751A1 (en) * | 2002-09-13 | 2006-10-26 | Marmo J C | Corneal onlays and methods of producing same |
US7828844B2 (en) * | 2002-09-13 | 2010-11-09 | Forsight Labs, Llc | Inserting lenses into corneal epithelial pockets to improve vision |
US20060134170A1 (en) * | 2004-08-13 | 2006-06-22 | May Griffith | Vision enhancing ophthalmic devices and related methods and compositions |
US20070182920A1 (en) * | 2006-02-08 | 2007-08-09 | Coopervision, Inc. | Corneal Onlays and Related Methods |
US20070239184A1 (en) * | 2006-04-10 | 2007-10-11 | Markus Gaeckle | Corneal epithelial pocket formation systems, components and methods |
US7883520B2 (en) | 2006-04-10 | 2011-02-08 | Forsight Labs, Llc | Corneal epithelial pocket formation systems, components and methods |
US20100087920A1 (en) * | 2008-10-07 | 2010-04-08 | Forsight Labs, Llc | Corneal Onlay Lenses and Related Methods for Improving Vision of Presbyopic Patients |
US10285857B2 (en) | 2010-09-30 | 2019-05-14 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US11033429B2 (en) | 2010-09-30 | 2021-06-15 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US11135090B2 (en) | 2010-09-30 | 2021-10-05 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US10092594B2 (en) | 2012-03-29 | 2018-10-09 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US11931291B2 (en) | 2012-03-29 | 2024-03-19 | Epion Therapeutics, Inc. | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
US9555111B2 (en) | 2012-03-29 | 2017-01-31 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US10575986B2 (en) | 2012-03-29 | 2020-03-03 | Cxl Ophthalmics, Llc | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
US11497766B2 (en) | 2012-03-29 | 2022-11-15 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US10729716B2 (en) | 2012-03-29 | 2020-08-04 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US10564447B2 (en) | 2013-11-20 | 2020-02-18 | Iwane Mitsui | Contact lens for corrected-cornea crosslinking, corrected-cornea crosslinking method, and ring-shaped contact lens |
US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US11565023B2 (en) * | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
US10278920B1 (en) * | 2014-05-12 | 2019-05-07 | Gholam A. Peyman | Drug delivery implant and a method using the same |
US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
Also Published As
Publication number | Publication date |
---|---|
US20030083743A1 (en) | 2003-05-01 |
US20030105521A1 (en) | 2003-06-05 |
EP1301223A2 (en) | 2003-04-16 |
AU2001278947B2 (en) | 2006-03-30 |
JP2004504627A (en) | 2004-02-12 |
CN1243573C (en) | 2006-03-01 |
MXPA03000511A (en) | 2004-09-10 |
CA2418306A1 (en) | 2002-01-24 |
IL153969A0 (en) | 2003-07-31 |
US20050124982A1 (en) | 2005-06-09 |
WO2002006883A2 (en) | 2002-01-24 |
WO2002006883A3 (en) | 2002-05-23 |
US6880558B2 (en) | 2005-04-19 |
IL153969A (en) | 2006-12-10 |
CN1458849A (en) | 2003-11-26 |
AU7894701A (en) | 2002-01-30 |
US6544286B1 (en) | 2003-04-08 |
KR20030045779A (en) | 2003-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6880558B2 (en) | Method of lifting an epithelial layer and placing a corrective lens beneath it | |
AU2001278947A1 (en) | Pre-fabricated corneal tissue lens and method of corneal overlay to correct vision (ii) | |
US7828844B2 (en) | Inserting lenses into corneal epithelial pockets to improve vision | |
US5196026A (en) | Method of implanting corneal inlay lenses smaller than the optic zone | |
Riau et al. | Stromal keratophakia: corneal inlay implantation | |
US5139518A (en) | Methods employed in replacement of the corneal endothelium | |
US20140155871A1 (en) | Method for preparing corneal donor tissue for refractive eye surgery utilizing the femtosecond laser | |
US9937033B1 (en) | Corneal lenslet implantation with a cross-linked cornea | |
El Zarif et al. | Corneal stromal regeneration: a review of human clinical studies in keratoconus treatment | |
US11259914B2 (en) | Molding or 3-D printing of a synthetic refractive corneal lenslet | |
US10709546B2 (en) | Intracorneal lens implantation with a cross-linked cornea | |
US9744029B1 (en) | Method of preventing capsular opacification and fibrosis utilizing an accommodative intraocular lens implant | |
CN1694658A (en) | Devices and methods for improving vision | |
US20220409361A1 (en) | Ablatable Corneal Inlay For Correction Of Refractive Errors And/Or Presbyopia | |
US20230404805A1 (en) | Tissue-Augmented Corneal Inlay Surgery Technique | |
Kalinnikov et al. | Surgical technique of keratoplasty with simultaneous implantation of a continuous ring or ring segment into the graft | |
KR100305222B1 (en) | Artificial cornea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |